|
Sex
| | |
0.100
| | |
0.092
|
|
Male
|
1.00
| | |
1.00
| | |
|
Female
|
2.42
|
(0.85–6.93)
| |
3.40
|
(0.82–14.15)
| |
|
Age (years)
|
1.01
|
(0.96–1.07)
|
0.633
| | | |
|
Time from diagnosis to ART (months)
|
0.98
|
(0.94–1.01)
|
0.183
| | | |
|
Transmission route
| | |
0.857
| | | |
|
Homosexual
|
1.00
| | | | | |
|
Heterosexual
|
1.36
|
(0.44–4.27)
| | | | |
|
Others
|
1.42
|
(0.20–9.82)
| | | | |
|
HIV-1 subtype
| | |
0.717
| | | |
|
AE
|
1.00
| | | | | |
|
B/C/BC
|
1.48
|
(0.37–5.96)
|
0.584
| | | |
|
Others
|
1.68
|
(0.48–5.95)
|
0.418
| | | |
|
ART therapy
| | |
0.477
| | | |
|
AZT/d4T + 3TC + NVP
|
1.00
| | | | | |
|
TDF + 3TC + EFV
|
0.67
|
(0.22–2.04)
| | | | |
|
Plasma viral load at enrollment (log copies/mL)
|
0.71
|
(0.36–1.41)
|
0.330
| | | |
|
HIV-1 DNA at enrollment (log copies/106 PBMCs)
|
0.72
|
(0.17–3.11)
|
0.656
| | | |
|
CD4+ T-cell count at enrollment (cells/μL)
|
1.00
|
(1.00–1.01)
|
0.134
| | | |
|
Nadir CD4+ T-cell count (cells/μL)
|
1.00
|
(1.00–1.01)
|
0.129
| | | |
|
CD8+ T-cell count at enrollment (cells/μL)
|
1.00
|
(1.00–1.00)
|
0.528
| | | |
|
CD4/CD8 ratio at enrollment
|
1.19
|
(0.95–1.48)
|
0.124
| | | |
|
Plasma viral load at week 96
| | |
0.808
| | | |
|
Undetectable
|
1.00
| | | | | |
|
Viremia
|
0.75
|
(0.07–7.66)
| | | | |
|
CD4+ T-cell count at week 96 (cells/μL)
|
1.00
|
(1.00–1.00)
|
0.709
| | | |
|
CD8+ T-cell count at week 96 (cells/μL)
|
0.99
|
(0.99–0.99)a
|
0.018
|
1.00
|
(0.99–1.00)
|
0.462
|
|
CD4/CD8 ratio at week 96 (per 0.1 increase)
|
1.28
|
(1.05–1.55)
|
0.014
|
1.29
|
(1.05–1.59)
|
0.017
|
